Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
KRKatherine R TuttleSJSibylle J. HauskeMEMaría Eugênia Fernandes CanzianiMLMaria Luiza CaramoriDZDavid Z.I. Cherney
Providence College · University of Washington · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
182
total citations
- FWCI
- 32.66
- Percentile
- 100%
- References
- 31
Citations per year
Authors
561- KRKatherine R TuttleCorresponding
Providence College, University of Washington, Inland Northwest Health Services, Providence Health & Services
- SJSibylle J. Hauske
Boehringer Ingelheim (Germany), Heidelberg University, University Medical Centre Mannheim
- MEMaría Eugênia Fernandes Canziani
Universidade Federal de São Paulo
- MLMaria Luiza Caramori
University of Minnesota, Cleveland Clinic, Cleveland Foundation
- DZDavid Z.I. Cherney
Toronto General Hospital
Topics & keywords
Topics
Keywords
- Empagliflozin
- Medicine
- Aldosterone
- Kidney disease
- Aldosterone synthase
- Randomized controlled trial
- Internal medicine
- Pharmacology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.